144 related articles for article (PubMed ID: 16149296)
21. [Molecular-targeted therapy in the developing stage. 1) VEGFR-TKI and EGFR-TKI].
Yano S
Nihon Naika Gakkai Zasshi; 2009 Aug; 98(8):1887-93. PubMed ID: 19894348
[No Abstract] [Full Text] [Related]
22. Pressure sore-like ulcers on acneiform papules caused by EGFR inhibitors.
Miyawaki S; Tohyama M; Irifune K; Ito R; Sayama K
Int Wound J; 2014 Oct; 11(5):569-70. PubMed ID: 23517492
[No Abstract] [Full Text] [Related]
23. Approved use of gefitinib.
Lyle J
Am J Health Syst Pharm; 2004 Oct; 61(19):2008; author reply 2008. PubMed ID: 15509120
[No Abstract] [Full Text] [Related]
24. Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.
Mochizuki S; Nishimura N; Inoue A; Murakami K; Nukiwa T; Chohnabayashi N
Respir Investig; 2012 Sep; 50(3):117-21. PubMed ID: 23021771
[TBL] [Abstract][Full Text] [Related]
25. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
Graves JE; Jones BF; Lind AC; Heffernan MP
J Am Acad Dermatol; 2006 Aug; 55(2):349-53. PubMed ID: 16844529
[TBL] [Abstract][Full Text] [Related]
26. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.
William WN; Gold KA; Kim ES
Ann Oncol; 2009 Sep; 20(9):1455-1457. PubMed ID: 19704160
[No Abstract] [Full Text] [Related]
27. Molecular selection trumps clinical selection.
Shepherd FA
J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
[No Abstract] [Full Text] [Related]
28. Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer.
Bonomi PD
Am J Health Syst Pharm; 2003 Dec; 60(24 Suppl 9):S16-21. PubMed ID: 14717024
[TBL] [Abstract][Full Text] [Related]
29. Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?
Normanno N; Di Maio M; Perrone F; Campiglio M
J Clin Oncol; 2004 May; 22(10):2035-6; author reply 2036-7. PubMed ID: 15143103
[No Abstract] [Full Text] [Related]
30. Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?
Noberasco C; De Pas T; Curigliano G; Manzoni S; Dodaro L; Pelosi G; Spaggiari L; De Braud F
J Clin Oncol; 2005 Feb; 23(4):921-2; author reply 922. PubMed ID: 15681541
[No Abstract] [Full Text] [Related]
31. Despite concerns, FDA panel backs EGFR inhibitor.
Twombly R
J Natl Cancer Inst; 2002 Nov; 94(21):1596-7. PubMed ID: 12419780
[No Abstract] [Full Text] [Related]
32. [Gefitinib in non-small cell lung cancer].
Nakagawa K
Nihon Rinsho; 2004 Jul; 62(7):1312-20. PubMed ID: 15283149
[No Abstract] [Full Text] [Related]
33. [Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer].
Lv P; Zhou T
Zhongguo Fei Ai Za Zhi; 2010 Mar; 13(3):247-53. PubMed ID: 20673523
[No Abstract] [Full Text] [Related]
34. Late fatal recurrence in gefitinib-treated NSCLC patients.
Miyazaki K; Ano T; Nakazawa K; Satoh H; Ohtsuka M
Tuberk Toraks; 2007; 55(4):400-3. PubMed ID: 18224510
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
36. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
[TBL] [Abstract][Full Text] [Related]
37. [Iressa (gefitinib)].
Kudoh S; Yoshimura A; Gemma A
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1079-84. PubMed ID: 12938261
[TBL] [Abstract][Full Text] [Related]
38. From bench to bedside and back again?
CMAJ; 2004 Jun; 170(12):1765, 1767. PubMed ID: 15184306
[No Abstract] [Full Text] [Related]
39. [Advanced lung cancer of performance status 3 successfully treated by gefitinib--a case report].
Kambayashi T; Ishibashi O; Yanagihara K; Tanaka F; Hasegawa S; Wada H
Gan To Kagaku Ryoho; 2004 Feb; 31(2):223-6. PubMed ID: 14997756
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib or docetaxel in advanced non-small-cell lung cancer.
Cullen M; Thatcher N
Lancet; 2008 Nov; 372(9652):1785-6. PubMed ID: 19027472
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
